/
Infectious Disease
Hepatitis B
43
Pipeline Programs↗
50
Active Trials↗
35
Companies Involved↗
Hepatitis B is a moderately active landscape with 43 programs across 35 companies. The most active players are Gilead, Beijing Continent Pharmaceutical Co, Ltd., GSK. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical28
Phase 16
Phase 36
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
24 of 35 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 100% of 43 pipeline programs.
Analysis
Trial Status
311
clinical trials
Completed187 · 60%
Unknown status56 · 18%
Recruiting23 · 7%
Not yet recruiting14 · 5%
Terminated11 · 4%
Active, not recruiting10 · 3%
Other10 · 3%
Clinical Trials
Trial Activity
311 trials
Page 1 of 21
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)